Plasma oxytocin changes and anti-obsessive response during serotonin reuptake inhibitor treatment: a placebo controlled study

Table 4 Correlations of plasma oxytocin measures with anti-obsessive and anti-depressive responses to SRI and OCD severity

	Y-BOCS, % decrease at endpoint	MADRS, % decrease at endpoint	Y-BOCS at baseline	NIMH-GOCS decrease at endpoint	PGE score at endpoint
OT baseline, n = 27	0.23	-0.05	0.52**	0.25	-0.33
OT week 1, n = 27	-0.34	-0.18	0.25	-0.22	0.04
OT week 4, n = 24	0.31	0.15	0.43*	0.43*	-0.49*
OT change from baseline to week 4, n = 24	-0.14	-0.14	-0.13	-0.20	0.12
OT first week change, n = 27	-0.49**	-0.13	-0.15	-0.40*	0.26
OT change from week 1 to week 4, n = 24	0.58**	0.26	-0.02	0.46*	-0.38
OT range, n = 27	0.59**	0.49**	0.38	0.67***	-0.66***

Only patients treated with SRI are included (n = 27). Nonparametric correlations (Spearman’s rho) are reported. Bold-italic numbers indicate correlations that remained significant after Bonferroni adjustment, when applied for the first two columns.
MADRS = Montgomery Åsberg Depression Rating Scale; NIMH-GOCS = National Institute of Mental Health Global Obsessive Compulsive Scale; PGE = Patient’s Global Evaluation; OCD = obsessive-compulsive disorder; OT = plasma oxytocin; OT range = intra-individual range between the highest and the lowest of each patient’s 3 (n = 24) or 2 (n = 3) OT samples; SRI = serotonin reuptake inhibitor; Y-BOCS = Yale-Brown Obsessive Compulsive Scale.
*p < 0.05; **p < 0.01; ***p < 0.001.

ISSN: 1471-244X